Simulations from the pharmacokinetics-pharmacodynamics model of phase 2A AIDS Clinical Trials Group (ACTG) A5312/INHindsight study revealed that 10 and 15 mg/kg doses of isoniazid are required for inhA-mutated isolates in slow and intermediate NAT2 acetylators, respectively, to achieve a drop in bacterial load comparable to 5 mg/kg against drug-sensitive tuberculosis, whereas NAT2 fast acetylators underperformed even at doses of 15 mg/kg [64]. Here, NAT2 is linked to tuberculosis.